(15) followed up with a trial (NCT00829166) using T-DM1 in HER2-positive advanced breast cancer patients previously treated with trastuzumab and paclitaxel, and they found that T-DM1 significantly prolonged progression-free (PFS) and overall survival (OS) and was less toxic than lapatinib plus capecitabine. Here, ERBB2 is linked to breast carcinoma.